Organon & (US:OGN) ZACKSยท2024-10-14 23:06Group 1: Company Performance - Organon closed at $18.10, with a +0.56% change from the previous day, lagging behind the S&P 500's gain of 0.77% [1] - The stock has decreased by 12.07% over the past month, underperforming the Medical sector's loss of 3% and the S&P 500's gain of 4.87% [1] Group 2: Upcoming Earnings - Organon's earnings report is expected on October 31, 2024, with projected earnings of $0.97 per share, indicating a year-over-year growth of 11.49% [2] - The Zacks Consensus Estimate for revenue is $1.56 billion, reflecting a 2.44% increase from the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $4.34 per share and revenue at $6.34 billion, showing changes of +4.83% and +1.28% respectively from the prior year [3] Group 4: Analyst Estimates - Recent changes to analyst estimates for Organon are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which considers these estimate changes, provides an operational rating system for investors [5] Group 5: Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.3% in the past month [6] - The company has a Forward P/E ratio of 4.14, significantly lower than the industry average of 20.29, and a PEG ratio of 0.75 compared to the industry average of 1.81 [7] Group 6: Industry Context - The Medical Services industry, which includes Organon, has a Zacks Industry Rank of 192, placing it in the bottom 24% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]